Cardiac medications in obstetric patients

Curr Opin Cardiol. 2023 May 1;38(3):266-274. doi: 10.1097/HCO.0000000000001039. Epub 2023 Mar 28.

Abstract

Purpose of review: This review summarizes recent literature, updated safety data, and major clinical considerations for commonly used medications for arrhythmias, heart failure, hypertension, ischemic heart disease, and anticoagulation during pregnancy and lactation.

Recent findings: Recent studies have shown a benefit to more aggressive treatment of mild chronic hypertension to a blood pressure goal of <140/90 with oral labetalol and nifedipine remaining first-line agents. Aspirin is now routinely used for preeclampsia prevention, while experience with other antiplatelet agents, such as purinergic receptor P2Y G protein-coupled 12 (P2Y12) inhibitors, continues to grow. Data on statin therapy are rapidly changing and recent studies suggest this class may not be associated with fetal harm and can be continued in select cases.

Summary: As data regarding medication safety continues to evolve, a multidisciplinary team is needed for full consideration of maternal and fetal risks and benefits. Ongoing studies are needed to improve and expand our understanding of medication safety during pregnancy and lactation.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Aspirin / therapeutic use
  • Cardiovascular Agents* / adverse effects
  • Cardiovascular Agents* / therapeutic use
  • Female
  • Hematologic Agents* / adverse effects
  • Hematologic Agents* / therapeutic use
  • Humans
  • Hypertension / drug therapy
  • Labetalol / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Pre-Eclampsia / drug therapy
  • Pregnancy*

Substances

  • Antihypertensive Agents
  • Aspirin
  • Labetalol
  • Platelet Aggregation Inhibitors
  • Cardiovascular Agents
  • Hematologic Agents